Tumor chemopotentiation using isocoumarin derivatives
AssigneeILWZ ILEX Products, Inc.
InventorsNaoki Agata, Surender Kharbanda
Life of this patent
Estimating the term…
Abstract
A method for enhancing the efficacy of chemotherapy in the treatment of cancer in animals, particularly humans, is provided wherein isocoumarin derivatives that exhibit unique chemopotentiation properties are employed in a combination treatment with chemotherapy.
Claims20
A method for inducing cell death in a cancer cell, comprising contacting said cancer cell with an isocoumarin derivative of the formula:
- 4
- and further contacting said cancer cell with a glucocorticoid, wherein the dose of said isocoumarin derivative when combined with the dose of said glucocorticoid is effective to induce cell death in said cancer cell.
The method of claim 2, wherein said inducing cell comprises inducing apoptosis.
The method of claim 4, wherein said glucocorticoid is dexamethasone or prednisone.
A method for inhibiting the proliferation of a cancer cell, comprising contacting said cancer with an isocoumarin derivative of the formula:
- 5
- and further contacting said cancer cell with a glucocorticoid, wherein the dose of said isocoumarin derivative when combined with the dose of said glucocorticoid is effective to inhibit the proliferation of said cancer cell.
A method for treating multiple myeloma in a human patient, comprising administering an isocoumarin derivative of the formula:
- 6
- and administering a glucocorticoid as a second treatment modality, wherein the administration of said isocoumarin derivative when combined with the administration of said glucocorticoid, is effective to treat said multiple myeloma.
A method for treating multiple myeloma in a human patient, comprising administering an isocoumarin derivative of the formula:
- 7
- and administering a glucocorticoid as a second treatment modality and administering one or more other chemotherapeutic agents as further treatment modalities, wherein the administration of said isocoumarin derivative when combined with the administration said glucocorticoid and administration of said one or more other chemotherapeutic agents is effective to treat said multiple myeloma.
Dependencies are inferred from the claim text.